'On consolidated basis
Quarter ended December 2024 compared with Quarter ended December 2023.
Net sales (including other operating income) of Sanofi India has increased 9.74% to Rs 514.9 crore. Operating profit margin has jumped from 21.23% to 22.98%, leading to 18.78% rise in operating profit to Rs 118.30 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 17.17% to 16.94%. Purchase of finished goods cost rose from 28.03% to 39.34%. Employee cost decreased from 15.90% to 8.87%. Other expenses fell from 17.04% to 15.34%.
Other income fell 37.23% to Rs 5.9 crore. PBIDT rose 13.94% to Rs 124.2 crore. Loan funds rose to Rs 19.30 crore as of 31 December 2024 from Rs 19.00 crore as of 31 December 2023. Inventories declined from Rs 663.80 crore as of 31 December 2023 to Rs 499.80 crore as of 31 December 2024. ...
Pleaselogin & subscribe to view the full report.
More Reports
-
(13-Jan-2026)
HCL Technologies
Revenue up 13.3% YoY to Rs 33872 crore in Q3FY2026
-
(13-Jan-2026)
Tata Consultancy Services
Revenue up 4.9% YoY to Rs 67087 crore in Q3FY2026
-
(12-Jan-2026)
Krishana Phoschem
Revenue up 116.8% YoY to Rs 659 crore in Q3FY2026
-
(11-Jan-2026)
Avenue Supermarts
Revenue up 13.3% YoY to Rs 18100.9 crore, Net profit up 18.3% yoy to Rs 855.9 crore in Q3FY2026
|
|